SciELO - Scientific Electronic Library Online

 
vol.21 issue1Accuracy of sacroiliac joint (SIJ) bone scintigraphy in the diagnosis of sacroiliitis in a Colombian cohort with spondyloarthritis (SpA)Characterization of health-related quality of life studies in people with psoriasis: Systematic review 2003-2013 author indexsubject indexarticles search
Home Pagealphabetic serial listing  

Services on Demand

Journal

Article

Indicators

Related links

  • On index processCited by Google
  • Have no similar articlesSimilars in SciELO
  • On index processSimilars in Google

Share


Revista Colombiana de Reumatología

Print version ISSN 0121-8123

Abstract

VEGA MIRANDA, Juliana et al. Infections in rheumatoid arthritis patients: Biological therapy versus disease modifying anti-rheumatic drugs: One year follow-up. Rev.Colomb.Reumatol. [online]. 2014, vol.21, n.1, pp.27-34. ISSN 0121-8123.

Background: Disease modifying anti-rheumatic drugs and biological disease modifying drugs are used to control inflammation and prevent progression of joint damage in rheumatoid arthritis. It is still controversial whether these drugs increase the incidence of infection in this disease. Methods: A retrospective cohort study was conducted on a population sample of 383 inpatients and outpatients from a university hospital and referral rheumatology tertiary hospital complex in northwestern Colombia. They were classified according to American College of Rheumatology 1987 classification criteria, with 83 in the biological therapy group, and 300 in the disease modifying antirheumatic drugs group, in order to establish the incidence and risk factors for serious and non-serious infections at 12 months follow-up. Results: The majority were females (85%). The biological therapy group presented a greater risk for non-serious [HR 1.73 (95% CI 1.07-2.77; P=.023)] and serious infections [HR 2.56 (95% CI 1.09-6.01; P=.030)]. This finding remained when adjusting for other variables associated with infection (number of disease modifying antirheumatic drugs received, methotrexate, leflunomide and steroids use, diabetes mellitus), with HR for non-serious infection [(1.67, 95% CI 1.05-2.70; P=.030)], and HR for serious infection [(2.67, 95% CI 1.12-6.34; P=.026)]. Chronic lung disease [HR 5.11 (95 % CI 1.18-22.08; P=.029)] was an additional risk factor for serious infections. Conclusions: Biological therapy increases the risk of serious and non-serious infections at 12 months, compared to disease modifying drugs, in a group of patients with rheumatoid arthritis. The risk of serious infections also increases with the presence of chronic lung disease.

Keywords : Arthritis rheumatoid; Biological therapy; Antirheumatic agents.

        · abstract in Spanish     · text in Spanish     · Spanish ( pdf )